title: Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study.
abstract: OBJECTIVE
  The acute morbidity of doses of 64.8-75.6 Gy and preliminary observations of late complications and tumor response using 3-dimensional conformal radiation therapy in carcinoma of the prostate are assessed.
  
  
  METHODS
  123 patients (Stage A2-12, B1-17, B2-43, C-51) were irradiated to the prostate and seminal vesicles using a 3-dimensional conformal radiation therapy technique. The median follow-up time was 15.2 months. The minimum tumor dose was 64.8-66.6 Gy in 49 patients, 70.2 Gy in 46, and 75.6 Gy in 28. Toxicity was scored according to the Radiation Therapy Oncology Group morbidity grading system.
  
  
  RESULTS
  This technique of 3-dimensional conformal radiation therapy was well-tolerated with minimal acute morbidity. Only 32% of patients had grade 2 or 3 acute morbidity requiring short-term medication for relief of urinary symptoms or diarrhea. Only one patient (0.8%) has so far developed a severe (grade 4) late complication. Serum prostate specific antigen concentrations normalized in 67% of patients (64/96) within 1-14 months (median 4.5 months) after treatment and were progressively decreasing at last measurement in an additional 22% (21/96). Abnormal rising prostate specific antigen levels were observed in 15 patients, 11 of whom have already developed other evidence of relapsing disease.
  
  
  CONCLUSIONS
  Acute toxicity for the doses tested with this 3-dimensional conformal radiation therapy technique is reduced compared to traditional treatment techniques, and the initial tumor response as assessed by prostate specific antigen measurement is highly encouraging with prostate specific antigen levels returning to normal in the majority of patients. Based on these results, a further increase of the dose to 81 Gy has been implemented in accordance with the schema of an ongoing Phase I dose-escalation study.
authors.affiliation: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021.
authors.forename: S A
authors.initials: SA
authors.lastname: Leibel
authors.forename: R
authors.initials: R
authors.lastname: Heimann
authors.forename: G J
authors.initials: GJ
authors.lastname: Kutcher
authors.forename: M J
authors.initials: MJ
authors.lastname: Zelefsky
authors.forename: C M
authors.initials: CM
authors.lastname: Burman
authors.forename: E
authors.initials: E
authors.lastname: Melian
authors.forename: J P
authors.initials: JP
authors.lastname: Orazem
authors.forename: R
authors.initials: R
authors.lastname: Mohan
authors.forename: T J
authors.initials: TJ
authors.lastname: LoSasso
authors.forename: Y C
authors.initials: YC
authors.lastname: Lo
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000276:immunology / Q000532:radiotherapy*; D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000276:immunology / Q000532:radiotherapy*; D011882:Radiotherapy, High-Energy / Q000009:adverse effects / Q000379:methods*
chemical_list: D017430:Prostate-Specific Antigen